JP2022516919A - Ｒｎａをモジュレートするためのシステムおよび方法 - Google Patents

Ｒｎａをモジュレートするためのシステムおよび方法 Download PDF

Info

Publication number
JP2022516919A
JP2022516919A JP2021538952A JP2021538952A JP2022516919A JP 2022516919 A JP2022516919 A JP 2022516919A JP 2021538952 A JP2021538952 A JP 2021538952A JP 2021538952 A JP2021538952 A JP 2021538952A JP 2022516919 A JP2022516919 A JP 2022516919A
Authority
JP
Japan
Prior art keywords
rna
cirts
domain
protein
hairpin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021538952A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022516919A5 (https=
Inventor
ブライアン シー． ディキンソン
シモーネ ラウチ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
University of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Chicago filed Critical University of Chicago
Publication of JP2022516919A publication Critical patent/JP2022516919A/ja
Publication of JP2022516919A5 publication Critical patent/JP2022516919A5/ja
Priority to JP2025030993A priority Critical patent/JP2025084877A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/85—Fusion polypeptide containing an RNA binding domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
JP2021538952A 2019-01-04 2020-01-03 Ｒｎａをモジュレートするためのシステムおよび方法 Pending JP2022516919A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025030993A JP2025084877A (ja) 2019-01-04 2025-02-28 Ｒｎａをモジュレートするためのシステムおよび方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962788571P 2019-01-04 2019-01-04
US62/788,571 2019-01-04
US201962831342P 2019-04-09 2019-04-09
US62/831,342 2019-04-09
US201962903080P 2019-09-20 2019-09-20
US62/903,080 2019-09-20
US201962929339P 2019-11-01 2019-11-01
US62/929,339 2019-11-01
PCT/US2020/012169 WO2020142676A1 (en) 2019-01-04 2020-01-03 Systems and methods for modulating rna

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025030993A Division JP2025084877A (ja) 2019-01-04 2025-02-28 Ｒｎａをモジュレートするためのシステムおよび方法

Publications (2)

Publication Number Publication Date
JP2022516919A true JP2022516919A (ja) 2022-03-03
JP2022516919A5 JP2022516919A5 (https=) 2023-01-26

Family

ID=71407144

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021538952A Pending JP2022516919A (ja) 2019-01-04 2020-01-03 Ｒｎａをモジュレートするためのシステムおよび方法
JP2025030993A Pending JP2025084877A (ja) 2019-01-04 2025-02-28 Ｒｎａをモジュレートするためのシステムおよび方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025030993A Pending JP2025084877A (ja) 2019-01-04 2025-02-28 Ｒｎａをモジュレートするためのシステムおよび方法

Country Status (12)

Country Link
US (1) US20220048962A1 (https=)
EP (1) EP3906042A4 (https=)
JP (2) JP2022516919A (https=)
KR (1) KR20210124238A (https=)
CN (1) CN113543797A (https=)
AU (2) AU2020204917A1 (https=)
BR (1) BR112021013173A2 (https=)
CA (1) CA3125299A1 (https=)
IL (1) IL284516A (https=)
MX (1) MX2021008153A (https=)
SG (1) SG11202107209WA (https=)
WO (1) WO2020142676A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210095296A1 (en) * 2019-09-29 2021-04-01 Technion Research & Development Foundation Limited Synthetic non-coding rnas
EP4110918A4 (en) * 2020-02-28 2024-04-03 The University of Chicago METHODS AND COMPOSITIONS COMPRISING TRANS-ACTING TRANSLATION ACTIVATORS
CN113583136A (zh) * 2021-04-25 2021-11-02 南方科技大学 一种植物激素脱落酸荧光分子探针及其用途
WO2022251264A1 (en) * 2021-05-24 2022-12-01 Donald Danforth Plant Science Center Compositions for rna-protein tethering and methods of using
JP2023040984A (ja) * 2021-09-10 2023-03-23 国立大学法人信州大学 Ｒｎａの編集方法及びｒｎａを編集するためのキット
KR20240082405A (ko) * 2021-10-08 2024-06-10 펜슬 바이오사이언시스 리미티드 합성 게놈 편집 시스템
CN114085837B (zh) * 2021-11-19 2024-04-12 中山大学 一种敲除基因ythdf1的细胞系及其构建方法
WO2023150131A1 (en) * 2022-02-01 2023-08-10 The Regents Of The University Of California Method of regulating alternative polyadenylation in rna
US20250154508A1 (en) * 2022-02-25 2025-05-15 The University Of Chicago Methods and compositions for activating translation
CN114685685B (zh) * 2022-04-20 2023-11-07 上海科技大学 编辑rna的融合蛋白及其应用
US20250283062A1 (en) * 2022-05-02 2025-09-11 The University Of Chicago Systems and methods for modulating rna
EP4689118A1 (en) * 2023-03-31 2026-02-11 Duke University Compositions for and methods of engineering the transcriptome
GB202401827D0 (en) * 2024-02-09 2024-03-27 Ucl Business Ltd Therapy for dravet syndrome
CN119899820B (zh) * 2025-01-23 2026-04-03 深圳开悦生命科技有限公司 Dhx8融合蛋白及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108559738A (zh) * 2018-02-12 2018-09-21 南昌大学 一种植物rna修饰和编辑的系统及方法
WO2018191388A1 (en) * 2017-04-12 2018-10-18 The Broad Institute, Inc. Novel type vi crispr orthologs and systems

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077082A1 (en) * 2002-10-18 2004-04-22 Koehn Richard K. RNA-based inhibitory oligonucleotides
PL3360964T3 (pl) * 2012-12-06 2020-03-31 Sigma-Aldrich Co. Llc Modyfikacja i regulacja genomu oparta na crispr
EP4286517A3 (en) * 2013-04-04 2024-03-13 President and Fellows of Harvard College Therapeutic uses of genome editing with crispr/cas systems
EP3341410B1 (en) * 2015-08-24 2021-06-02 Cellectis Chimeric antigen receptors with integrated controllable functions
US20200291369A1 (en) * 2016-03-11 2020-09-17 Erasmus University Medical Center Rotterdam Improved CRISPR-Cas9 Genome Editing Tool
CA3025523A1 (en) * 2016-05-27 2017-11-30 Aadigen, Llc Peptides and nanoparticles for intracellular delivery of genome-editing molecules
CN110612353A (zh) * 2017-03-03 2019-12-24 加利福尼亚大学董事会 经由抑制性tRNAs和脱氨酶对突变进行RNA靶向

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018191388A1 (en) * 2017-04-12 2018-10-18 The Broad Institute, Inc. Novel type vi crispr orthologs and systems
CN108559738A (zh) * 2018-02-12 2018-09-21 南昌大学 一种植物rna修饰和编辑的系统及方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CELL, vol. 178, no. 1, JPN6024001085, 27 June 2019 (2019-06-27), pages 122 - 134, ISSN: 0005236913 *
GENE THER, vol. 24, no. 12, JPN6024001084, 7 December 2017 (2017-12-07), pages 779 - 786, ISSN: 0005450953 *
SCIENCE, vol. 358, no. 6366, JPN7024000075, 25 October 2017 (2017-10-25), pages 1019 - 1027, ISSN: 0005236912 *

Also Published As

Publication number Publication date
SG11202107209WA (en) 2021-07-29
JP2025084877A (ja) 2025-06-03
KR20210124238A (ko) 2021-10-14
WO2020142676A1 (en) 2020-07-09
EP3906042A4 (en) 2023-03-15
EP3906042A1 (en) 2021-11-10
IL284516A (en) 2021-08-31
CN113543797A (zh) 2021-10-22
MX2021008153A (es) 2021-08-11
US20220048962A1 (en) 2022-02-17
AU2026200853A1 (en) 2026-04-02
BR112021013173A2 (pt) 2021-09-28
AU2020204917A1 (en) 2021-08-19
CA3125299A1 (en) 2020-07-09

Similar Documents

Publication Publication Date Title
JP2022516919A (ja) Ｒｎａをモジュレートするためのシステムおよび方法
JP7709487B2 (ja) Ｃｒｉｓｐｒｃｐｆ１の結晶構造
US20200299661A1 (en) Cpf1-related methods and compositions for gene editing
US20240376499A1 (en) Modular prime editing systems for genome engineering
KR20160097327A (ko) 유전자 산물, 구조 정보 및 유도성 모듈형 ｃａｓ 효소의 발현의 변경을 위한 ｃｒｉｓｐｒ-ｃａｓ 시스템 및 방법
CN108601821A (zh) 包含经修饰的人T细胞受体α恒定区基因的经遗传修饰的细胞
JP2020513783A (ja) Ｃｒｉｓｐｒ
JP2024041866A (ja) 強化されたｈＡＴファミリーのトランスポゾンが介在する遺伝子導入ならびに関連する組成物、システム、及び方法
US20240425832A1 (en) Compositions and methods of genome editing
JP2021519101A (ja) ドナーｄｎａを連結するための改変型核酸編集システム
US20250283062A1 (en) Systems and methods for modulating rna
CA3247727A1 (en) VEGF MODULATION METHOD AND ITS USE
Tachikawa et al. Targeting the human genome
HK40060450A (en) Systems and methods for modulating rna
WO2025255510A1 (en) Systems and methods for modulating rna
US20250034548A1 (en) Improved modular prime editing with modified effectors and templates
HK40120944B (zh) 基因组编辑的组合物和方法
HK40120944A (zh) 基因组编辑的组合物和方法
HK40115932A (zh) 调节vegf的方法及其用途
CA3026112A1 (en) Cpf1 complexes with reduced indel activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230116

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240412

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240709

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241101